Grapefruit USA, Inc. Provides Further Update on Diagnostic Lab Corporation, Inc. Acquisition, Securing New Financing
November 21, 2022
Ryan Allway November 21st, 2022 News, Top News LOS ANGELES and DESERT HOT SPRINGS, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) — via InvestorWire — Grapefruit USA, Inc. (OTCQB: GPFT) (“Grapefruit” or the “Company”), an innovative California-based cannabiotech company, is updating its recent announcement of the proposed acquisition of Diagnostic... Read more
Evogene (EVGN) Reports Q3 Loss, Tops Revenue Estimates
November 17, 2022
Ryan Allway November 17th, 2022 News, Top News Thu, November 17, 2022 – Evogene (EVGN) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.19 per share a year ago. These figures are... Read more
MyMD Pharmaceuticals® Announces Upcoming Presentation of Late-Breaking Data for MYMD-1® at the 2022 British Society for Immunology (BSI) Congress
November 17, 2022
Ryan Allway November 17th, 2022 News, Top News – Preclinical and early clinical studies of MYMD-1®, an oral, small-molecule, selective TNF-α inhibitor accepted for presentation – BALTIMORE, November 17, 2022–(BUSINESS WIRE)–MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company developing groundbreaking therapies for the treatment of serious... Read more
Ryan Allway November 17th, 2022 News, Top News VANCOUVER, BC, Nov. 17, 2022 /PRNewswire/ – Xebra Brands Ltd. (“Xebra”) (CSE: XBRA) (OTCQB: XBRAF) (FSE: 9YC), a cannabis company, provides an update on the issuance of its Mexican cannabis authorizations. Xebra Brands Ltd. (CNW Group/Xebra Brands Ltd.) Xebra previously announced that it expected the... Read more
Clearmind Medicine Announces Closing of US$7.5 Million Public Offering and Uplisting to the Nasdaq Capital Market
November 17, 2022
Ryan Allway November 17th, 2022 News, Top News VANCOUVER, Nov. 17, 2022 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq and CSE: CMND), (FSE: CWY) (“Clearmind” or the “Company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, today announced the closing of... Read more
Evogene Reports Third Quarter 2022 Financial Results
November 17, 2022
Ryan Allway November 17th, 2022 News, Top News Conference call and webcast: today, November 17, 2022, 9:00 am ET REHOVOT, Israel, Nov. 17, 2022 /PRNewswire/ — Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science based product discovery and development utilizing cutting edge computational biology technologies, across multiple... Read more
Mindset Pharma and PharmAla Enter into Exclusive Sales Agreement for the Sale and Distribution of Pharmaceutical Grade Psilocybin
November 16, 2022
TORONTO, Nov. 16, 2022 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, and PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA), a biotechnology company focused... Read more
22nd Century Group’s GVB Biopharma Opens New Central Distribution Facility in The Netherlands
November 16, 2022
Ryan Allway November 16th, 2022 News, Top News New distribution facility supports rapidly growing demand for hemp/cannabis products BUFFALO, N.Y., Nov. 16, 2022 (GLOBE NEWSWIRE) — GVB Biopharma, a 22nd Century Group company (Nasdaq: XXII), today announced that it has opened a new, strategically-located distribution facility in the Netherlands to support... Read more
Software Effective Solutions’ (OTC: SFWJ) Medcana Subsidiaries Launch Construction Proceedings for Multiple Greenhouse Operation
November 16, 2022
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any... Read more
Royal Emerald Pharmaceuticals Partners with BioHarvest Sciences to Supply Disruptive Cannabis Solutions to Companies Conducting FDA-Approved Medical Research
November 16, 2022
Ryan Allway November 16th, 2022 BioHarvest Sciences (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV), a leading biotech company focused on plant bio-cells growth for the nutraceutical and the medicinal cannabis markets, today announced the signing of a binding Letter of Intent (LOI) with Royal Emerald Pharmaceuticals (REP), one of only... Read more
